Total Funding
6
67
Total FundingVenture - Series Unknown raised
Growth Score
1 pts
Heat Score
5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
67407
Euclises Pharmaceuticals develops novel COX-2 inhibitors for the effective treatment of cancers in the lungs, colon, and pancreas.
- Bobby Sandage: President & CEOPast Role: Fortress Biotech, President and CEO
George H. Capps: Director of Business DevelopmentPast Role: Indalo Therapeutics, VP & Head of Business Operations:
About the Company
Euclises Pharmaceuticals, Inc is developing novel pain and cancer medications that offer superior safety margins compared to existing drugs. The company is based on new inventions from Dr. John Talley, the most accomplished medicinal chemist in the world. Dr. Talley previously invented Celebrex and seven other approved drugs. New compounds from
Euclises will offer both improved efficacy and safety relative to existing therapies. Euclises is located at the BioGenerator Accelerator Labs.
South Asian Led
